Anonymous
Guest
Anonymous
Guest
Amitiza remains resilient to Linzess threat
Commercialised by US partner, Takeda, with 18-23% royalties payable to Sucampo, prescriptions and sales of Amitiza in the US continue to grow and appear largely unaffected by the introduction of Ironwood/Forest’s Linzess. Despite being priced at a 14% discount to Amitiza ($7.10 vs $8.23) and supported by a massive promotional campaign, so far Linzess has not had a direct impact on Amitiza, instead helping to grow the market for the use of Rx drugs for constipation disorders by attracting new patients and those previously using OTC laxatives.
Commercialised by US partner, Takeda, with 18-23% royalties payable to Sucampo, prescriptions and sales of Amitiza in the US continue to grow and appear largely unaffected by the introduction of Ironwood/Forest’s Linzess. Despite being priced at a 14% discount to Amitiza ($7.10 vs $8.23) and supported by a massive promotional campaign, so far Linzess has not had a direct impact on Amitiza, instead helping to grow the market for the use of Rx drugs for constipation disorders by attracting new patients and those previously using OTC laxatives.